MDL supports clinical research across a broad spectrum of oncology therapeutics, medical devices, and surgical interventions, with experience spanning chemotherapy and cytotoxic therapies, targeted and precision therapies, immuno-oncology, hormonal therapies, supportive and palliative care products, and combination treatment approaches. Our expertise also extends to surgical oncology, minimally invasive and laparoscopic procedures, robot-assisted oncological surgery, implantable and procedure-specific medical devices, and technology-enabled cancer care, supporting clinical evaluation across different stages of the oncology treatment pathway.

Cardiovascular research at MDL encompasses cardiovascular diseases, pharmacotherapies, medical devices, and interventional procedures, covering coronary, structural, rhythm, vascular, and heart-failure care.

Our experience covers coronary artery disease, acute coronary syndromes, hypertension, dyslipidemia, heart failure, atrial fibrillation and other arrhythmias, valvular heart disease, peripheral vascular disorders, and thromboembolic conditions. We support studies involving antiplatelet and anticoagulant therapies, lipid-lowering agents, antihypertensives, antianginal and antiarrhythmic therapies, heart-failure treatments, and emerging cardiometabolic therapies.

Our device and procedural expertise includes advanced coronary stents, angioplasty and catheter-based interventions, atherectomy systems, vascular and carotid stents, PTCA balloons, transcatheter valve therapies, structural-heart devices, left atrial appendage closure, pacemakers, leadless cardiac pacing, implantable defibrillators, cardiac resynchronization therapy, electrophysiology mapping and ablation systems, including pulsed-field ablation, and cardiovascular monitoring and hemodynamic technologies.

Through an integrated approach to pharmaceutical, device, diagnostic, and interventional research, MDL supports evidence generation across the evolving cardiovascular treatment landscape